A case for improved carrier screening
Expanded carrier screening addresses limitations in historical ethnic-based screenings, including potential racial and ethnic bias....
New Clinical Tool Predicts 1- and 2-Year Mortality in Cystic Fibrosis
Researchers in Canada have developed a novel clinical tool that uses patients’ overall health status and the risk for intermittent shock...
Paying more attention to antibiotic dosing could improve clinical outcomes for CF patients
Download PDF Copy Children and young adults with cystic fibrosis (CF) whose lung infections were treated with suboptimal doses of...
Savara Provides Update on IMPALA and AVAIL Pivotal Clinical Studies
AUSTIN, Texas, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today provided an update on...
Link Found Between P. aeruginosa Infection and Disease Severity in CF Patients, Study Reports
Patients with cystic fibrosis (CF) whose lungs have never been colonized by the Pseudomonas aeruginosa bacterium have a milder form of...
Data from Clinical and Pre-Clinical Trials Evaluating Verona Pharma’s RPL554 in Cystic Fibrosis Pres
Pre-clinical findings show RPL554 stimulates rare class III and IV CFTR mutants Phase 2a results demonstrate RPL554 has favorable...
Does Monotherapy With Correctors Have Clinical Benefit in Cystic Fibrosis?
Insufficient evidence exists to demonstrate that monotherapy with correctors has clinically important effects in individuals with cystic...
